about
Cholestatic jaundice caused by cloxacillin: macrophage inhibition factor test in preventing rechallenge with hepatotoxic drugsComparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics.Mezlocillin for treatment of infections in cancer patientsPotential of mezlocillin as empiric single-agent therapy in febrile granulocytopenic cancer patientsEffects of cytotoxic and immunosuppressive agents on the immune system.Granulocyte transfusion therapy of experimental Pseudomonas pneumoniaComparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.Clinical and pharmacological studies of ticarcillin in gram-negative infectionsPirbenicillin, a new semisynthetic penicillin with broad-spectrum activitySynergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.Clinical pharmacology of ticarcillin (alpha-carboxyl-3-thienylmethyl penicillin, BRL-2288)Ticarcillin therapy of infections.Association of serum soluble triggering receptor expressed on myeloid cells levels in malignant febrile neutropenic patients with bacteremia and fungemia.Comparison of serum bactericidal activity among three antimicrobial combinations.Pseudomonas aeruginosa infection in cancer patients.Controversies in the management of febrile neutropenic cancer patients.Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patientsPseudomonas aeruginosa infections.The role of the newer beta-lactam antibiotics in the treatment of infection in compromised hosts.Bacteriological and clinical studies of sulbenicillin.Platelet dysfunction induced by parenteral carbenicillin and ticarcillin. Studies of the dose-response relationship and mechanism of action in dogs.In vitro sensitivity of isolates of Pseudomonas aeruginosa to carbenicillin, gentamicin, tobramycin, and some other antibiotics.Pathogenesis and treatment of facial paralysis due to malignant external otitis.
P2860
Q28367195-A35A7043-FF6E-4BD8-A896-5E1C135012D0Q33726819-43BF8BBC-AA3C-40D1-9249-D6F8F7168384Q33730391-F387013E-39D6-4485-8D44-B2C5ABACCBA7Q33731809-1ED60674-53DA-4315-9021-1B04771C3392Q34072063-B3A1A8A8-B11F-4082-AEA3-F3AE3445E0FDQ34466736-D876CF19-35DF-434C-81E7-1E3EDAD55F1EQ34961824-0743B298-12A7-4985-AE89-F59D9DEA98F1Q34962007-6839FF63-5513-4C6E-A887-01204F09A514Q34973927-B42FA81C-013F-4E2B-986A-25654BD6897CQ34981359-3E8FD725-452D-436E-AD79-5F2BE1629957Q35540674-A67BF6E3-5628-4335-9CAA-E57532EDFDE5Q35651079-FB5B27EB-99F5-42E5-85E2-7EDE0E585071Q35653667-D09180CE-A116-48BD-AD40-CFDDA0E49A62Q36244907-08A632CA-CDC8-49C2-AAC9-D20C39C20D55Q36471007-2C8C2A7C-997E-4336-B651-6044A1FF9999Q36756527-78AA49BC-8BD4-4CB6-98A2-D9FEF79B64CCQ39603225-72F6784E-F6D2-4940-BF06-F26839B49147Q39833436-8D4196BD-9E3E-430C-AB08-310FF4733585Q39903765-DBD36FED-41A6-4899-9662-6C0565079FD9Q40177254-733E2245-2418-410E-9963-6C322EC71B0EQ40960865-633AE5F5-4E5E-4BCD-991C-950BD288ED57Q41854409-9357537F-0BE8-4311-86E1-C1EBAE36F6A1Q53956607-1E52DF30-24F1-4CB2-B2DB-A033B8160BAEQ54490183-8B847F1A-EEFB-421F-9DB9-EDA5F1D7943C
P2860
description
1971 nî lūn-bûn
@nan
1971年の論文
@ja
1971年学术文章
@wuu
1971年学术文章
@zh-cn
1971年学术文章
@zh-hans
1971年学术文章
@zh-my
1971年学术文章
@zh-sg
1971年學術文章
@yue
1971年學術文章
@zh
1971年學術文章
@zh-hant
name
Carbenicillin therapy for pseudomonas infections.
@en
Carbenicillin therapy for pseudomonas infections.
@nl
type
label
Carbenicillin therapy for pseudomonas infections.
@en
Carbenicillin therapy for pseudomonas infections.
@nl
prefLabel
Carbenicillin therapy for pseudomonas infections.
@en
Carbenicillin therapy for pseudomonas infections.
@nl
P2093
P1476
Carbenicillin therapy for pseudomonas infections.
@en
P2093
E Middleman
J P Whitecar
V Rodriguez
P356
10.1001/JAMA.1971.03190140038007
P407
P577
1971-10-01T00:00:00Z